NCT05451251 Deep Brain Stimulation for Refractory Trigeminal Neuralgia with a Pontine Lesion
| NCT ID | NCT05451251 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Université de Sherbrooke |
| Condition | Trigeminal Neuralgia |
| Study Type | INTERVENTIONAL |
| Enrollment | 6 participants |
| Start Date | 2024-10-15 |
| Primary Completion | 2025-10-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 6 participants in total. It began in 2024-10-15 with a primary completion date of 2025-10-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to assess the feasibility of deep brain stimulation for refractory trigeminal neuralgia due to a pontine lesion, as is usually seen in the context of multiple sclerosis. These patients usually have severe intractable facial pain and current medical and surgical options generally fail to achieve long lasting pain relief. Hoping to improve pain control in this population, the investigators of this trial propose a novel technique consisting of implanting a deep brain stimulation lead within the pontine lesion to modulate the generation of pain signals.
Eligibility Criteria
Inclusion Criteria: * Adults of at least 18 years old * Refractory trigeminal neuralgia : failure of at least 3 drugs and at least two lesioning surgical interventions (radiosurgery, percutaneous rhizotomy, or open rhizotomy). * Pontine lesion proved by MRI in contact with trigeminal nerve tract Exclusion Criteria: * Absolute contraindication to MRI * Medical contraindication to the procedure
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05451251 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Trigeminal Neuralgia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05451251 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT05451251 currently recruiting?
Yes, NCT05451251 is actively recruiting participants. Contact the research team at Christian.Iorio-Morin@usherbrooke.ca for enrollment information.
Where is the NCT05451251 trial being conducted?
This trial is being conducted at Sherbrooke, Canada.
Who is sponsoring the NCT05451251 clinical trial?
NCT05451251 is sponsored by Université de Sherbrooke. The trial plans to enroll 6 participants.